Mean (range) | |
---|---|
Age (years) | 56.7 (34–89) |
N (%) | |
Histology | |
Benign | 1 (1.3) |
Malignant | 78 (98.7) |
Invasive lobular carcinoma | 15 (19.2) |
Invasive ductal carcinoma | 55 (70.5) |
Miscellaneusa | 4 (5.1) |
Unknownb | 4 (5.1) |
Grading (G)* | |
G 1–2 | 32 (41.0) |
G3 | 40 (51.3) |
Unknownc | 6 (7.7) |
Hormon receptor status* | |
dER+/ePgR+ | 57 (73.1) |
ER+/PgR- | 12 (15.4) |
ER−/PgR- | 6 (7.7) |
Unknown f | 3 (3.8) |
Her2 Status* | |
Positive | 12 (15.2) |
Surgical procedures | |
Surgical procedures with curative intent | 79 (100) |
Simple excision/lumpectomy | 2 (2.5) |
Breast conserving surgery | 29 (36.7) |
gMastectomy | 23 (29.1) |
hNipple sparing mastectomy | 19 (24.0) |
iSkin reducing mastectomy | 6 (7.6) |
Surgical procedures with recostructive intent | 48 (60.7) |
Pre-pectoral DTIj | 16 (33.3) |
Sub-pectoral DTI | 4 (8.3) |
Pre-pectoral TEk | 1 (2.1) |
Sub-pectoral TE | 13 (27.1) |
Contralateral symmetrization | 4 (8.3) |
Surgical procedures with prophilactic intent** | |
Concomitant bilateral oophorectomy | 2 (2.5) |
Neo-adjuvant chemotherapy | |
Yes | 13 (16.7) |
Pathologic complete response | |
Yes | 5 (38.5) |
lASA risk score | |
1–2 | 60 (76.0) |
3–4 | 19 (24.0) |